Corporate Update: Leadership, Regulatory Milestones, and Financial Strengthening

Governance Enhancements

Carvolix has announced the appointment of Anne Lange as chair of its board. The company states that her experience in clinical strategy and international market expansion will accelerate the execution of its growth plan. This leadership change coincides with a broader board reshuffle that added a new observer and expanded the scientific advisory board. The expanded advisory body is intended to strengthen governance oversight and to bring additional expertise to the company’s portfolio of heart‑related technologies, particularly in the context of expanding its international footprint.

Regulatory Progress on Key Platforms

Carvolix’s first‑half 2026 results underscore sustained progress on its flagship TAVIPILOT platform, a combined software‑driven decision support system and robotic‑assisted aortic valve intervention solution.

  • CE Marking Dossier – The company has filed the complete CE marking dossier for the TAVIPILOT software, indicating compliance with European Union medical device directives and facilitating market access in EU member states.
  • FDA Filing – A pre‑market submission for the TAVIPILOT robotic arm has been filed with the U.S. Food and Drug Administration. The filing includes comprehensive pre‑clinical data, device characterization, and an early‑access study protocol.
  • Clinical Outcomes – Data from the New York Valves programme demonstrate high procedural success rates, with a significant reduction in procedure time (average 15 % shorter) and imaging exposure (average 20 % lower fluoroscopy dose). These findings align with current evidence that robotic assistance can improve efficiency while maintaining or enhancing procedural safety.

The company’s Kalios Mitral Ring also reported encouraging results over a three‑year follow‑up. All enrolled patients achieved the predefined primary endpoint—defined as a reduction in mitral regurgitation severity by at least two grades—without any device‑related adverse events. The absence of late‑onset complications supports the long‑term safety profile of the Kalios platform.

Financial Position

Carvolix secured additional capital in the first half of 2026, consisting of:

  • Equity Tranche – €10 million of new equity, providing direct shareholder investment and a reduction in debt burden.
  • Structured Bond Package – €30 million of structured bonds, offering a flexible debt instrument with favorable interest terms.

The combined €40 million capital injection is earmarked for ongoing clinical development, regulatory submissions, and scaling manufacturing capabilities. These funds also position the company to pursue strategic partnerships and to accelerate commercialization in emerging markets.

Market Presence and Strategic Initiatives

Carvolix’s inclusion in multiple Euronext indices has increased visibility among institutional investors. The company has also attracted coverage from several research and rating agencies, reinforcing its financial and operational credibility.

In addition, Carvolix announced the launch of a French‑Saudi Medical Exchange Programme. This initiative aims to foster collaboration in interventional cardiology and neurovascular procedures by facilitating knowledge transfer, joint clinical trials, and shared best practices between French and Saudi healthcare systems. The exchange is expected to open new market opportunities and to provide a platform for collaborative research that aligns with the company’s global strategy.

Implications for Patient Care and Healthcare Systems

The regulatory milestones achieved for TAVIPILOT suggest that, pending final approvals, the platform could become available to a broader patient population seeking minimally invasive aortic valve intervention. The demonstrated reductions in procedure time and imaging exposure have the potential to decrease operative costs, improve patient throughput, and lower cumulative radiation exposure for both patients and staff.

The Kalios Mitral Ring’s favorable safety and efficacy profile may broaden the therapeutic options for patients with mitral regurgitation, potentially reducing the need for surgical intervention and associated morbidity.

Carvolix’s strengthened governance structure and increased capital base provide a robust foundation for scaling production and ensuring consistent supply, which is critical for meeting the demands of growing healthcare systems. The strategic partnership initiatives further enable the company to tailor its solutions to diverse regulatory environments and clinical practices worldwide.

Conclusion

Carvolix’s recent corporate announcements reflect a comprehensive strategy that integrates leadership realignment, regulatory advancement, financial fortification, and international collaboration. These developments collectively support the company’s ambition to become a global leader in heart‑related medical technology while maintaining a rigorous focus on safety, efficacy, and regulatory compliance.